Multiple studies have shown tumor tissue expression of PD-L1, and drugs that inhibit the interaction of this checkpoint pathway have demonstrated remarkable clinical efficacy in a variety of cancers (e.g., bladder, lung, kidney, and melanoma)4,5. The gene discussed is CD274; the disease is cancer.